Clinical trials
Phase 3 Bacterial Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 5 |
| 2003 | 4 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 8 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 53 |
| Terminated | 6 |
| Unknown status | 3 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Wyeth is now a wholly owned subsidiary of Pfizer | 5 |
| MCM Vaccines B.V. | 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| Pfizer | 4 |
| Bayer | 3 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 3 |
| Melinta Therapeutics, Inc. | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Achaogen, Inc. | 2 |
| CanSino Biologics Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bacterial Infections | 65 |
| Infections | 8 |
| Cellulitis | 7 |
| Virus Diseases | 7 |
| Whooping Cough | 7 |
| Gram-Positive Bacterial Infections | 6 |
| Communicable Diseases | 5 |
| Immune System Diseases | 5 |
| Rare Diseases | 5 |
| Skin Diseases, Bacterial | 5 |
Trials
Showing 26 to 50 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.